Advanced thyroid carcinoma is an infrequent tumor entity with limited treatment possibilities
until recently. The extraordinary improvement in the comprehension of genetic and …

Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic
chemotherapy. However, newer advances in the understanding of the molecular …

Introduction: While the vast majority of patients with thyroid cancer have an excellent
prognosis, those with more aggressive courses experience significant morbidity and …

Historically, systemic therapies for advanced, metastatic thyroid carcinomas have been
poorly effective. However, as a result of a confluence of increasing knowledge of the biologic …

Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have
historically been limited. Recent progress in understanding the pathogenesis of the various …

Surgery and radioiodine therapy are usually effective for most patients with differentiated
thyroid cancer. However, poorly differentiated and anaplastic thyroid carcinomas represent a …

Differentiated thyroid carcinoma (DTC) accounts for more than 90% of new thyroid cancer
diagnoses, and includes papillary, follicular and Hürthle cell carcinoma. The prognosis for …

Introduction: Patients with progressive, metastatic, RAI-refractory differentiated thyroid
cancer (DTC), as well as patients with advanced medullary (MTC) and anaplastic thyroid …

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most
aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on …

Although thyroid cancer represents less than 1% of malignant tumours, its increased
incidence detected in recent years and the appearance and development of new drugs …